Company intelligence / Profile preview
Syntrix Pharmaceuticals
- Ownership
- Private
- Development stage
- Phase 2
Overview
Syntrix Pharmaceuticals has demonstrated clinical activity with its lead candidate SX‑682—a dual CXCR1/2 inhibitor—in patients with myelodysplastic syndromes who failed front-line hypomethylating agents. The company also has additional assets in pain management and autoimmunity at various stages of development. Its pipeline includes both internally discovered small molecules and externally sourced innovations.
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- Small moleculesBiologics (proteins or antibodies)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Syntrix Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Syntrix Pharmaceuticals.